S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
How High Can Copper Go? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Top 10 Searched Stocks on MarketBeat All-Access
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
How High Can Copper Go? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Top 10 Searched Stocks on MarketBeat All-Access
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
How High Can Copper Go? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Top 10 Searched Stocks on MarketBeat All-Access
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
How High Can Copper Go? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Top 10 Searched Stocks on MarketBeat All-Access
NASDAQ:TCON

TRACON Pharmaceuticals - TCON Stock Forecast, Price & News

$1.41
-0.04 (-2.76%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.41
$1.45
50-Day Range
$1.40
$1.77
52-Week Range
$1.24
$3.79
Volume
27,367 shs
Average Volume
63,956 shs
Market Capitalization
$30.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

TRACON Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
609.2% Upside
$10.00 Price Target
Short Interest
Healthy
0.69% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$139,341 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.14) to ($1.00) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

524th out of 1,027 stocks

Biological Products, Except Diagnostic Industry

86th out of 171 stocks

TCON stock logo

About TRACON Pharmaceuticals (NASDAQ:TCON) Stock

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Receive TCON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TCON Stock News Headlines

TRACON Pharmaceuticals (NASDAQ:TCON) Now Covered by StockNews.com
See More Headlines
Receive TCON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TCON Company Calendar

Last Earnings
11/03/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/21/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCON
Employees
19
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+609.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-28,670,000.00
Pretax Margin
-9,559.54%

Debt

Sales & Book Value

Annual Sales
$350,000.00
Book Value
$0.60 per share

Miscellaneous

Free Float
20,664,000
Market Cap
$30.20 million
Optionable
Not Optionable
Beta
1.33

Key Executives

  • Dr. Charles P. Theuer M.D. (Age 58)
    Ph.D., CEO, Pres & Director
    Comp: $827.53k
  • Mr. Scott B. Brown CPA (Age 41)
    M.S., Chief Financial Officer
    Comp: $459.21k
  • Ms. Bonne Adams (Age 45)
    Exec. VP of Clinical Operations
  • Mr. Shahe Garabedian
    Sr. VP & Head of Quality Assurance
  • Dr. James L. Freddo (Age 67)
    Chief Medical Officer
  • Mr. Ya Huang
    Exec. Director of Statistical Programming
  • Dr. Brenda Marczi Pharm.D.
    Pharmd Mba, Sr. VP of Regulatory Affairs













TCON Stock - Frequently Asked Questions

Should I buy or sell TRACON Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" TCON shares.
View TCON analyst ratings
or view top-rated stocks.

What is TRACON Pharmaceuticals' stock price forecast for 2023?

1 analysts have issued twelve-month target prices for TRACON Pharmaceuticals' stock. Their TCON share price forecasts range from $10.00 to $10.00. On average, they expect the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 609.2% from the stock's current price.
View analysts price targets for TCON
or view top-rated stocks among Wall Street analysts.

How have TCON shares performed in 2022?

TRACON Pharmaceuticals' stock was trading at $2.77 at the beginning of 2022. Since then, TCON stock has decreased by 49.1% and is now trading at $1.41.
View the best growth stocks for 2022 here
.

When is TRACON Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our TCON earnings forecast
.

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) announced its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by $0.06. During the same quarter in the previous year, the company posted ($0.38) EPS.

What other stocks do shareholders of TRACON Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).

When did TRACON Pharmaceuticals IPO?

(TCON) raised $47 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

Who are TRACON Pharmaceuticals' major shareholders?

TRACON Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Boothbay Fund Management LLC (1.21%), Two Sigma Advisers LP (0.47%) and Renaissance Technologies LLC (0.32%). Insiders that own company stock include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, Saundra L Pelletier and Scott B Brown.
View institutional ownership trends
.

How do I buy shares of TRACON Pharmaceuticals?

Shares of TCON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TRACON Pharmaceuticals' stock price today?

One share of TCON stock can currently be purchased for approximately $1.41.

How much money does TRACON Pharmaceuticals make?

TRACON Pharmaceuticals (NASDAQ:TCON) has a market capitalization of $30.20 million and generates $350,000.00 in revenue each year. The biopharmaceutical company earns $-28,670,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

How can I contact TRACON Pharmaceuticals?

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The official website for the company is www.traconpharma.com. The biopharmaceutical company can be reached via phone at (858) 550-0780, via email at ir@traconpharma.com, or via fax at 858-550-0786.

This page (NASDAQ:TCON) was last updated on 12/8/2022 by MarketBeat.com Staff